Mildronate (Meldonium Dihydrate)

Meldonium, the active ingredient in Mildronate, is a metabolic modulator presented as an oral tablet for oral use. It is employed to manage cardiovascular ischemic conditions such as angina pectoris, chronic heart failure and peripheral vascular disease in adult patients.

GNH USA supplies Mildronate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers. Its distribution network ensures timely delivery and regulatory compliance across multiple regions.

Meldonium is indicated for several cardiovascular conditions where myocardial energy metabolism is compromised. - Angina pectoris: reduces frequency and severity of chest pain episodes by improving myocardial energy efficiency and oxygen utilization. - Chronic heart failure: enhances cardiac output and exercise tolerance through better myocardial metabolism. - Ischemic heart disease: mitigates myocardial ischemia by shifting substrate utilization toward glucose. - Peripheral vascular disease: alleviates intermittent claudication symptoms by improving peripheral tissue perfusion.

Meldonium may be associated with several adverse reactions, ranging from mild, reversible symptoms to rare but serious conditions that require medical attention. Common Side Effects: - Nausea: mild stomach upset after dosing. - Headache: transient cranial pain. - Dizziness: light‑headed sensation on standing. - Gastrointestinal discomfort: abdominal pain or indigestion. - Insomnia: difficulty falling asleep. - Fatigue: reduced energy levels. - Dry mouth: decreased salivary secretion. Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm. - Severe hypotension: marked blood pressure drop. - Allergic reactions: rash, pruritus, or angioedema. - Elevated liver enzymes: signs of hepatic stress. - Pancreatitis: inflammation of the pancreas. - Stevens‑Johnson syndrome: severe skin and mucosal reaction. - Renal impairment: reduced kidney function.

When prescribing Meldonium, several precautionary measures should be observed to ensure patient safety. - Cardiovascular monitoring: assess blood pressure and heart rhythm regularly. - Renal function: evaluate kidney function before initiating therapy. - Hepatic function: monitor liver enzymes during treatment. - Elderly patients: start with lower doses and observe tolerance. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture.

Meldonium can interact with other medicines; awareness of major and moderate interactions helps avoid adverse outcomes. Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may increase bleeding risk. - Antiarrhythmic agents: potential additive effects on cardiac rhythm. - Other metabolic modulators: may amplify metabolic shifts. Moderate Interactions (Monitor Closely): - Beta‑blockers: possible enhanced hypotensive effect. - Statins: monitor for altered lipid metabolism. - Diuretics: watch for electrolyte disturbances.